INCREDB ID : 98
Home >> Investigator Page Previous      Next
Trivadi S. Ganesan, M.D., M.A., Ph.D., M.R.C.P., F.R.C.P.
Professor 
 
Amrita Institute of Medical Sciences and Research Centre
Department of Medical Oncology
Amrita Lane, AIMS, Ponekkara
Kochi - 682 041   
Kerala   
 
E-mail: tsganesan@aims.amrita.edu
 
URL: http://aimshospital.org/research/institute_of_molecular_medicine/inst_mole/cancerbiology/cancerbiology_trividi.html
 
Positions Held:
Position Affiliation Time Period
Chairman Amrita Institute of Molecular Medicine, Amrita Institute of Medical Sciences, Kochi, India Present
Associate Dean Research, Amritha Institute of Medical Sciences, Kochi, India
Head Weatherall Institute of Molecular Medicine, Oxford, UK 1990-2006
Consultant Churchill Hospital, Oxford, UK 1990-2005
 
Area of Specialization:
Oncology
Medical Oncology
Publications:
1. Xavier, T., Ganesan, T. S. and Menon, K. N.  A simple and efficient method for processing of cell lysates for two-dimensional gel electrophoresis. Electrophoresis. 2010.  31, 2429-2435. [PubMed]
2. Rustin, G. J., Shreeves, G., Nathan, P. D., Gaya, A., Ganesan, T. S., Wang, D., Boxall, J., Poupard, L., Chaplin, D. J., Stratford, M. R., Balkissoon, J. and Zweifel, M.  A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. British Journal of Cancer. 2010.  102, 1355-1360. [PubMed]
3. Paige, A. J., Zucknick, M., Janczar, S., Paul, J., Mein, C. A., Taylor, K. J., Stewart, M., Gourley, C., Richardson, S., Perren, T., Ganesan, T. S., Smyth, J. F., Brown, R. and Gabra, H.  WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis. European Journal of Cancer. 2010.  46, 818-825. [PubMed]
4. Kaliyadan, F. and Ganesan, T. S.  Lichen planus associated with imatinib mesylate. Indian Journal of Dermatology, Venereology and Leprology. 2009.  75, 527-528. [PubMed]
5. Verma, S. K., Ganesan, T. S. and Parker, P. J.  The tumour suppressor RASSF1A is a novel substrate of PKC. FEBS Letters. 2008.  582, 2270-2276. [PubMed]
6. Sundar, S. S. and Ganesan, T. S.  Role of lymphangiogenesis in cancer. Journal of Clinical Oncology . 2007.  25, 4298-4307. [PubMed]
7. Madhusudan, S. and Ganesan, T. S.  Intraperitoneal gene therapy. Cancer Treatment and Research. 2007.  134, 515-524. [PubMed]
8. Madhusudan, S. and Ganesan, T. S.  Tyrosine kinase inhibitors and cancer therapy. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 2007.  172, 25-44. [PubMed]
9. Bignone, P. A., Lee, K. Y., Liu, Y., Emilion, G., Finch, J., Soosay, A. E., Charnock, F. M., Beck, S., Dunham, I., Mungall, A. J. and Ganesan, T. S.  RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene. 2007.  26, 683-700. [PubMed]
10. Sundar, S. S., Zhang, H., Brown, P., Manek, S., Han, C., Kaur, K., Charnock, M. F., Jackson, D. and Ganesan, T. S.  Role of lymphangiogenesis in epithelial ovarian cancer. British Journal of Cancer. 2006.  94, 1650-1657. [PubMed]
11. Nicke, B., Bastien, J., Khanna, S. J., Warne, P. H., Cowling, V., Cook, S. J., Peters, G., Delpuech, O., Schulze, A., Berns, K., Mullenders, J., Beijersbergen, R. L., Bernards, R., Ganesan, T. S., Downward, J. and Hancock, D. C.  Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells. Molecular Cell. 2005.  20, 673-685. [PubMed]
12. Madhusudan, S., Muthuramalingam, S. R., Braybrooke, J. P., Wilner, S., Kaur, K., Han, C., Hoare, S., Balkwill, F. and Ganesan, T. S.  Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. Journal of Clinical Oncology. 2005.  23, 5950-5959. [PubMed]
13. Levitt, N. C., Propper, D. J., Madhusudan, S., Braybrooke, J. P., Echeta, C., Te, P., Davies, S. L., Flanagan, E., Hickson, I. D., Joel, S. and Ganesan, T. S.  Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. British Journal of Cancer. 2005.  93, 60-69. [PubMed]
14. Madhusudan, S., Foster, M., Muthuramalingam, S. R., Braybrooke, J. P., Wilner, S., Kaur, K., Han, C., Hoare, S., Balkwill, F., Talbot, D. C., Ganesan, T. S. and Harris, A. L.  A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clinical Cancer Research. 2004.  10, 6528-6534. [PubMed]
15. Deplanque, G., Madhusudan, S., Jones, P. H., Wellmann, S., Christodoulos, K., Talbot, D. C., Ganesan, T. S., Blann, A. and Harris, A. L.  Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. British Journal of Cancer. 2004.  91, 1645-1650. [PubMed]
16. Madhusudan, S. and Ganesan, T. S.  Tyrosine kinase inhibitors in cancer therapy. Clinical Biochemistry. 2004.  37, 618-635. [PubMed]
17. Jones, P. H., Christodoulos, K., Dobbs, N., Thavasu, P., Balkwill, F., Blann, A. D., Caine, G. J., Kumar, S., Kakkar, A. J., Gompertz, N., Talbot, D. C., Ganesan, T. S. and Harris, A. L.  Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer. British Journal of Cancer. 2004.  91, 30-36. [PubMed]
18. Madhusudan, S., Tamir, A., Bates, N., Flanagan, E., Gore, M. E., Barton, D. P., Harper, P., Seckl, M., Thomas, H., Lemoine, N. R., Charnock, M., Habib, N. A., Lechler, R., Nicholls, J., Pignatelli, M. and Ganesan, T. S.  A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 2004.  10, 2986-2996. [PubMed]
19. Halford, S. E., Sawyer, E. J., Lambros, M. B., Gorman, P., Macdonald, N. D., Talbot, I. C., Foulkes, W. D., Gillett, C. E., Barnes, D. M., Akslen, L. A., Lee, K., Jacobs, I. J., Hanby, A. M., Ganesan, T. S., Salvesen, H. B., Bodmer, W. F., Tomlinson, I. P. and Roylance, R. R.  MSI-low, a real phenomenon which varies in frequency among cancer types. The Journal of Pathology. 2003.  201, 389-394. [PubMed]
20. Han, C., Braybrooke, J. P., Deplanque, G., Taylor, M., Mackintosh, D., Kaur, K., Samouri, K., Ganesan, T. S., Harris, A. L. and Talbot, D. C.  Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. British Journal of Cancer. 2003.  89, 1166-1171. [PubMed]
21. Jones, P. H., Burnett, R. D., Fainaru, I., Nadolny, P., Walker, P., Yu, Z., Tang-Liu, D., Ganesan, T. S., Talbot, D. C., Harris, A. L. and Rustin, G. J.  A phase 1 study of tazarotene in adults with advanced cancer. British Journal of Cancer. 2003.  89, 808-815. [PubMed]
22. Propper, D. J., Chao, D., Braybrooke, J. P., Bahl, P., Thavasu, P., Balkwill, F., Turley, H., Dobbs, N., Gatter, K., Talbot, D. C., Harris, A. L. and Ganesan, T. S.  Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clinical Cancer Research. 2003.  9, 84-92. [PubMed]
23. Propper, D. J., de, B., Saleem, A., Ellard, S., Flanagan, E., Paul, J., Ganesan, T. S., Talbot, D. C., Aboagye, E. O., Price, P., Harris, A. L. and Twelves, C.  Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. Journal of Clinical Oncology. 2003.  21, 203-210. [PubMed]
24. Liu, Y., Dodds, P., Emilion, G., Mungall, A. J., Dunham, I., Beck, S., Wells, R. S., Charnock, F. M. and Ganesan, T. S.  The human homologue of unc-93 maps to chromosome 6q27 - characterisation and analysis in sporadic epithelial ovarian cancer. BMC Genetics. 2002.  3, 20. [PubMed]
25. Trivier, E. and Ganesan, T. S.  RYK, a catalytically inactive receptor tyrosine kinase, associates with EphB2 and EphB3 but does not interact with AF-6. The Journal of Biological Chemistry. 2002.  277, 23037-23043. [PubMed]
26. Riddle, P. J., Echeta, C. B., Manek, S., Lavery, B. A., Charnock, F. M., Mackenzie, I. and Ganesan, T. S.  Retrospective study of management of uterine sarcomas at Oxford 1990-1998: role of adjuvant treatment. Clinical Oncology. 2002.  14, 54-61. [PubMed]
27. Liu, Y. and Ganesan, T. S.  Tumour suppressor genes in sporadic epithelial ovarian cancer. Reproduction. 2002.  123, 341-353. [PubMed]
28. Liu, Y., Emilion, G., Mungall, A. J., Dunham, I., Beck, S., Le, M., Shelling, A. N., Charnock, F. M. and Ganesan, T. S.  Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer. Oncogene. 2002.  21, 387-399. [PubMed]
29. L'hote, C. G., Thomas, P. H. and Ganesan, T. S.  Functional analysis of discoidin domain receptor 1: effect of adhesion on DDR1 phosphorylation. The FASEB Journal : Official Publication of the Federation of American Societies For Experimental Biology. 2002.  16, 234-236. [PubMed]
30. Propper, D. J., McDonald, A. C., Man, A., Thavasu, P., Balkwill, F., Braybrooke, J. P., Caponigro, F., Graf, P., Dutreix, C., Blackie, R., Kaye, S. B., Ganesan, T. S., Talbot, D. C., Harris, A. L. and Twelves, C.  Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2001.  19, 1485-1492. [PubMed]
31. Braybrooke, J. P., O'Byrne, K. J., Propper, D. J., Blann, A., Saunders, M., Dobbs, N., Han, C., Woodhull, J., Mitchell, K., Crew, J., Smith, K., Stephens, R., Ganesan, T. S., Talbot, D. C. and Harris, A. L.  A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clinical Cancer Research. 2000.  6, 4697-4704. [PubMed]
32. Odunsi, K. O., van, E. e., Ganesan, T. S. and Shelling, A. N.  Evaluation of the possible protective role of adeno-associated virus type 2 infection in HPV-associated premalignant disease of the cervix. Gynecologic Oncology. 2000.  78, 342-345. [PubMed]
33. Katso, R. M., Manek, S., Ganjavi, H., Biddolph, S., Charnock, M. F., Bradburn, M., Wells, M. and Ganesan, T. S.  Overexpression of H-Ryk in epithelial ovarian cancer: prognostic significance of receptor expression. Clinical Cancer Research. 2000.  6, 3271-3281. [PubMed]
34. Braybrooke, J. P., Vallis, K. A., Houlbrook, S., Rockett, H., Ellmen, J., Anttila, M., Ganesan, T. S., Harris, A. L. and Talbot, D. C.  Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Cancer Chemotherapy and Pharmacology. 2000.  46, 27-34. [PubMed]
35. Braybrooke, J. P., Propper, D. J., O'Byrne, K. J., Koukourakis, M. I., Patterson, A. V., Houlbrook, S., Love, S. D., Varcoe, S., Taylor, M., Ganesan, T. S., Talbot, D. C. and Harris, A. L.  Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. British Journal of Cancer. 2000.  83, 219-224. [PubMed]
36. Propper, D. J., Levitt, N. C., O'Byrne, K., Braybrooke, J. P., Talbot, D. C., Ganesan, T. S., Thompson, C. H., Rajagopalan, B., Littlewood, T. J., Dixon, R. M. and Harris, A. L.  Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. British Journal of Cancer. 2000.  82, 1776-1782. [PubMed]
37. Propper, D. J., Braybrooke, J. P., Levitt, N. C., O'Byrne, K., Christodoulos, K., Han, C., Talbot, D. C., Ganesan, T. S. and Harris, A. L.  Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. British Journal of Cancer. 2000.  82, 1759-1763. [PubMed]
38. O'Byrne, K. J., Philip, P. A., Propper, D. J., Braybrooke, J. P., Saunders, M. P., Bates, N. P., Taylor, M. A., Madigan, D., Ganesan, T. S., Talbot, D. C. and Harris, A. L.  A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 1999.  10, 981-983. [PubMed]
39. Propper, D. J., Braybrooke, J. P., Taylor, D. J., Lodi, R., Styles, P., Cramer, J. A., Collins, W. C., Levitt, N. C., Talbot, D. C., Ganesan, T. S. and Harris, A. L.  Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours. Annals of Oncology. 1999.  10, 923-927. [PubMed]
40. Katso, R. M., Russell, R. B. and Ganesan, T. S.  Functional analysis of H-Ryk, an atypical member of the receptor tyrosine kinase family. Molecular and Cellular Biology. 1999.  19, 6427-6440. [PubMed]
41. Propper, D. J., Saunders, M. P., Salisbury, A. J., Long, L., O'Byrne, K. J., Braybrooke, J. P., Dowsett, M., Taylor, M., Talbot, D. C., Ganesan, T. S. and Harris, A. L.  Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects. Clinical Cancer Research. 1999.  5, 1682-1689. [PubMed]
42. Katso, R. M., Manek, S., Biddolph, S., Whittaker, R., Charnock, M. F., Wells, M. and Ganesan, T. S.  Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer. Cancer Research. 1999.  59, 2265-2270. [PubMed]
43. Adams, M., Calvert, A. H., Carmichael, J., Clark, P. I., Coleman, R. E., Earl, H. M., Gallagher, C. J., Ganesan, T. S., Gore, M. E., Graham, J. D., Harper, P. G., Jayson, G. C., Kaye, S. B., Ledermann, J. A., Osborne, R. J., Perren, T. J., Poole, C. J., Radford, J. A., Rustin, G. J., Slevin, M. L., Smyth, J. F., Thomas, H. and Wilkinson, P. M.  Chemotherapy for ovarian cancer--a consensus statement on standard practice. British Journal of Cancer. 1998.  78, 1404-1406. [PubMed]
44. Propper, D. J., Macaulay, V., O'Byrne, K. J., Braybrooke, J. P., Wilner, S. M., Ganesan, T. S., Talbot, D. C. and Harris, A. L.  A phase II study of bryostatin 1 in metastatic malignant melanoma. British Journal of Cancer. 1998.  78, 1337-1341. [PubMed]

 
 
Education 
::
M.D. in General Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
::
M.A. University of Oxford, UK
::
Ph.D. University of London, UK
::
M.R.C.P.
::
F.R.C.P.
Member
::
National Academy of Medical Sciences
  Last modified on : Mar 4, 2011
India Cancer Research Database has been developed by the Institute of Bioinformatics with funding from the Department of Biotechnology, Government of India.